Recombinant interferon-alpha therapy in patients with follicular lymphoma.
BACKGROUND
Advanced stage, follicular, non-Hodgkin's lymphoma (NHL) has no cure and no single standard of care. Remissions induced by standard chemotherapy regimens generally are not durable and, with the exception of selected patients with limited early stage disease, most patients with follicular NHL eventually die of their disease. Recombinant interferon-alpha (rIFN-alpha) has demonstrated activity against follicular NHL in clinical trials.


METHODS
A comprehensive survey of current therapeutic options for follicular NHL patients was conducted with emphasis on the role of rIFN-alpha used in conjunction with chemotherapy regimens.


RESULTS
Phase III studies have demonstrated that rIFN-alpha delays disease progression and may improve overall survival when administered either with chemotherapy or as maintenance therapy after induction treatment for follicular lymphoma. Adverse effects from combination or maintenance regimens are not significantly different from those from chemotherapy alone.


CONCLUSIONS
Recombinant IFN-alpha is safe and effective when given in conjunction with standard chemotherapeutic regimens in selected patients with follicular NHL, and may especially benefit patients with minimal residual disease after induction chemotherapy.
Ozer
H
H
Allegheny University Cancer Center, Allegheny University of the Health Sciences, Philadelphia, Pennsylvania 19102, USA.
Wiernik
P H
PH
Giles
F
F
Tendler
C
C
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D011994:Recombinant Proteins; D012074:Remission Induction / Q000379:methods
D007370:Interferon Type I; D011994:Recombinant Proteins